Nuvectis Pharma Q1 net loss $4.0M; initiates Phase 1b for NXP800 in ovarian cancer

Nuvectis Pharma, Inc.

Cash $15.5M as of March 31, 2023 vs $20.0M at Dec 31, 2022; net loss $4.0M (Q1 2023) vs $2.9M (Q1 2022).
Phase 1b study of NXP800 in platinum-resistant ARID1a-mutated ovarian cancer initiated; multicenter trial with GOG Foundation and ENGOT.
IND for NXP900 pending; first-in-human trial expected shortly after IND becomes effective.
Mayo Clinic investigators presented in-vivo PDX data at AACR showing NXP800 potential in cholangiocarcinoma.
Company expects cash into H2 2024; R&D expenses $2.4M (up $0.6M YoY), G&A $1.7M (up $0.6M YoY).

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Nuvectis Pharma, Inc. reported first quarter 2023 results: net income Net loss was $4.0 million for the three months ended March 31, 2023.

Period: first quarter 2023
Net income: Net loss was $4.0 million for the three months ended March 31, 2023
Result: reported results

Exact text from the filing

Net loss was $4.0 million for the three months ended March 31, 2023

View on SEC.gov

Browse all earnings releases →

Nuvectis Pharma, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-058085

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.